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OBJECTIVE: To assess the effect of short-term testoster-
one enanthanate (T) supplementation on health-related
quality of life (HRQOL) in healthy, elderly males.
METHODS: As part of a double-blind, placebo-con-
trolled study, 22 healthy males  65 years were random-
ized to receive a total of 4 doses of T 200 mg or placebo
(P) intramuscularly every 2 weeks. HRQOL was assessed
using the SF-36 and Psychological General Well-Being
(PGWB) scales at baseline and after 8 weeks. Data was
analyzed using unpaired and paired t-tests, adjusting for
covariates. The study had 80% power to detect a 20-
point difference in 4 of the SF-36 domains and the PGWB
score; a P-value 0.05 was considered statistically signif-
icant. RESULTS: The mean age in the T (n  14) and P
(n  8) groups was 73.1  3.1 and 70.1  4.2 years, re-
spectively. Baseline PGWB scores were similar between
the groups (T:93.2,P:92.1). Baseline SF-36 scores were
similar between the groups: physical functioning (PF)
(T:93.9,P:82.5), role-physical (RP) (T:92.9,P:93.8), bodily
pain (BP) (T:86.1,P:81.6), general health (GH) (T:84.4,
P:76.9), social functioning (SF) (T:99.1,P:95.3), role-
emotional (RE) (T:90.4,P:100.0) and mental health
(MH) (T:84.7,P:76.0,); only vitality (VT) was signifi-
cantly different at baseline (T:80.4,P:65.6; P  0.007).
After 8 weeks, SF-36 scores were similar between the
groups:- PF (T:96.5,P:91.7), RP (T:92.3,P:100.0), BP
(T:91.5,P:87.2,), GH (T:87.1,P:79.2), VT (T:80.0,P:74.2),
SF (T:96.2,P:100.0), RE (T:89.7,P:100.0), MH (T:88.1,
P:90.0). PGWB scores were not significantly different be-
tween the groups (T:95.0,P:95.8) and there was no signif-
icant change within each group in HRQOL scores over
time. CONCLUSION: Healthy males  65 years have
high baseline HRQOL scores which are not enhanced by
short-term testosterone supplementation.
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The use of computerized databases to identify and follow
large cohorts of pregnant women make it feasible to
study trends in prescribing practices and to quickly iden-
tify defined cohorts of exposed pregnancies for further
research. OBJECTIVES: This study had two purposes, to
develop a methodology to identify pregnant women in an
automated database and determine the type and extent of
prescription drug use during a defined pregnancy period.
METHODS: A retrospective analysis of prescription
claims from an integrated managed care data base. The
study population consisted of women, aged 12–50 years
of age with a pregnancy indication during the period 10/
12/96–12/31/98. Pregnant women were identified using
ICD-9-CM diagnosis and procedure codes and CPT-4
codes. The pregnancy period was defined using date of
service fields. RESULTS: 4,732 women were identified
with a pregnancy during the specified time frame. 826
(17%) of these members had claims evidence of prescrip-
tion drug acquisition. Each woman received on average 2
different medications during pregnancy and an average
of 4.5 prescriptions. 25% of the prescription were agents
defined as pregnancy class C (prescription anthihistamine
agents, antiinfective agents and psychiatric medications
such as lithium and phenothiazines), 4% were defined as
pregnancy class D (antidepressant agents such as amitrip-
tyline and nortriptyline, anticonvulsant agents), and 7%
were classified as pregnancy class X (isotretinoin and es-
trogen preparations). Pregnancy class X poses the largest
concern. 115 women were identified with claims for oral
contraceptives that did not appear during the first or last
month of the pregnancy period. One woman was identi-
fied with claims for isotretinoin during the pregnancy pe-
riod. CONCLUSIONS: Information contained in the
claims data provides evidence regarding the use of pre-
scription drugs during pregnancy. Despite warnings in
literature and public media drugs defined as pregnancy
class X are acquired during the pregnancy period.
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Current trends in epidemiologic, economic and broader
effects of ED have implications for both public health
and patient QoL. Therefore evaluation of the impact of
the condition as well as new and competing treatments
must include assessment of QoL outcomes. Different
measures have been developed for assessing the impact of
ED and its treatments. Selection of one or more of these
measures for clinical research and practice must be based
on a careful comparison of published evidence of their
psychometric validity including responsiveness. OBJEC-
TIVES: To evaluate the psychometric properties and rele-
vance of measures used for assessing QoL in published
studies focusing on male sexual functioning in ill or well
subjects. METHODS: The literature search of MED-
LINE, EMBASE covered the period from 1966 to date
using various terms including QoL, satisfaction, impo-
tence and erectile dysfunction and was complemented by
a search of bibliographic data from our Information Re-
sources Center. RESULTS: 30 assessment tools have
been systematically reviewed in detail for their measure-
ment characteristics including psychometric properties.
These were made up of 19 sexuality/ED-specific mea-
sures, 3 generic multi-dimensional QoL instruments, 7
psychological scales and one satisfaction measure. We
found marked differences amongst instruments in terms
of domains covered and extent of psychometric valida-
tion of measures in the same taxonomic category. In par-
